Collegium Pharmaceutical, Inc. (COLL) CEO Joe Ciaffoni on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 02/28/20
Earnings Preview: Collegium Pharmaceutical (COLL) Q4 Earnings Expected to DeclineZacks Investment Research • 02/20/20
Collegium Pharmaceutical, Inc. Prices $125.0 Million Convertible Senior Notes OfferingGlobeNewsWire • 02/11/20
Market Is Turning A Blind Eye To Collegium's Lack Of Debt And Opioid LawsuitsSeeking Alpha • 12/03/19
About to Buy Penny Stock ? Look at These 3 Companies First: BE, COLL & SPWHThe Motley Fool • 11/20/19
Collegium Pharmaceutical, Inc. (COLL) CEO Joseph Ciaffoni on Q3 2019 Results - Earnings Call TranscriptSeeking Alpha • 11/07/19
Collegium Pharmaceutical (COLL) Reports Q3 Loss, Misses Revenue EstimatesZacks Investment Research • 11/06/19
Collegium: As Longstanding Opioid Companies Go Belly-Up, Collegium Looks To Stand OutSeeking Alpha • 09/23/19
Collegium Announces Scientific Presentations at PAINWeek 2019 National ConferenceGlobeNewsWire • 08/29/19
Collegium Pharmaceutical, Inc. (COLL) CEO Joe Ciaffoni on Q2 2019 Results - Earnings Call TranscriptSeeking Alpha • 08/08/19